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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the efficacy and effectiveness of singing interventions with non-singing intervention or usual care on QoL, wellbeing, and
speech and communication among people with PD. We will assess the QoL and the physical, psychological, and social health and
wellbeing of people with PD who receive a singing intervention, compared to non-singing intervention or usual care.
B A C K G R O U N D
For a glossary of terms see Table 1.
Description of the condition
Parkinson’s disease (PD) is a complex chronic neurological con-
dition that impacts upon a range of body functions. PD is
characterised primarily by progressively worsening symptoms of
movement abnormalities (e.g. bradykinesia, rigidity, and resting
tremor). People with PD can also experience sleep disturbance,
constipation, hyposmia, depression, and anxiety (Sutherland
2009). Furthermore, Parkinson’s disease affects speech function
due to the disturbances in muscular control of the speech mech-
anism (Herd 2012). The onset of PD is often unrecognised and
it may take some years for people living with PD to be diagnosed
(Mellick 2013).
Due to the chronic progressive nature of the disease, treatments
for people with Parkinson’s disease are complex and include med-
ications, surgical procedures, and rehabilitation therapies such as
physical, occupational, and speech therapy (Clarke 2007). Reha-
bilitation therapies focus on restoration of mobility and balance
(physiotherapy), improvement of personal self-care activities (oc-
cupational therapy), and alleviation of communication difficulties
(speech therapy) (Clarke 2007). Current pharmacotherapy can re-
duce Parkinson’s symptoms, but is associated with unwanted side-
effects, such as dyskinesia, dystonia, motor fluctuations, oedema,
somnolence, dizziness, and hallucinations (Stowe 2008). These
complications, and the increasing level of disability, significantly
influence quality of life (QoL) in people with PD (Rahman 2008).
Currently, there is no known cure and no therapy that can stall
PD progression.
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Description of the intervention
Singing is an accessible and popular form of musical activity. It
involves physical functions, such as engaging the vocal appara-
tus and respiratory system (Leanderson 1988), as well as mental
functions through emotional expression (Welch 2005). From a
neurological point of view, singing is a complex activity that in-
tegrates auditory and sensorimotor processes in the brain (Wan
2010). When singing, speech-related mechanisms, such as respi-
ration, phonation, articulation, and resonance, are directly stim-
ulated (Sundberg 1987).
How the intervention might work
Studies have found that participation in group singing or choirs
is associated with various health benefits across a wide range of
outcome groups, including enhanced physical functions andmen-
tal, social, and spiritual wellbeing (Clift 2010a; Clift 2010b; Irons
2012; Irons 2016). Singing may enhance health and wellbeing
through promoting neurochemicals such as dopamine, cortisol,
serotonin, and oxytocin, as the structures of songs (e.g. melody,
rhythm, and harmony) can induce a range of emotional and phys-
ical responses. For example, we may feel relaxed, peaceful, excited,
or happy when singing certain songs (Chanda 2013).
Singing has also been reported to be beneficial for people with
neurological conditions, such as PD, stroke, multiple sclerosis,
and dementia (Sihvonen 2017). It is posited that singing offers an
effective adjunct rehabilitation therapy for people with PD.
Quality of life
Several studies have suggested that participating in singing can
enhance a person’s QoL (Clift 2010a; Clift 2010b; Clift 2010c;
Johnson 2013). Singing studies specifically for people with PD
have also reported positive associations with enhanced QoL
(Stegemöller 2017; Reagon 2016).
Physical health
While singing, facial muscles, vocal apparatus (i.e. the lungs, vo-
cal cords in the larynx, mouth, and nasal cavities) and the whole
respiratory system (i.e. the lungs, diaphragm, and intercostal mus-
cles) are actively engaged to produce sounds (Sundberg 1987).
Regular singing practice can reduce communication difficulties in
people with PD (Evans 2012). Songs offer a range of pitch (low
and high), dynamics (soft and loud), and emotional expressions
through lyrics and harmony. Singing songs can provide an enjoy-
able exercise for people with PD, to retain or improve their com-
munication skills. An increasing number of studies report posi-
tive impacts of singing on the speech parameters (e.g. increased
loudness and phonation time) in people with PD (Evans 2012;
Haneishi 2001; Kempler 2002; Shih 2012). Evidence also sug-
gests that music can provide effective “auditory cueing” for peo-
ple with PD in relation to improving movements (Ashoori 2015;
Schaefer 2014; Thaut 2001). Rhythm and movements are natu-
rally connected. Songs contain rhythm, which serves as natural
timing for movements. A recent study has shown that listening to
familiar songs can help people with PD to organise their walking
movement efficiently (Leow 2015). Furthermore, through regular
singing, it is suggested that people with PD can experience en-
hanced lung function (Di Benedetto 2009).
Psychological health
Managing the chronic and progressive nature of PD requires pro-
found and prolonged adjustments to a person’s lifestyle, which
may impact psychosocial wellbeing. Depression and anxiety are
the most common and significant comorbid conditions (Broen
2016; Dissanayaka 2010; Dissanayaka 2011). Group singing pro-
grammes have been demonstrated to promote resilience and pro-
vide effective coping strategies in adults who have faced adverse
events (von Lob 2010).With regular singing activities (e.g. over six
months), people have reported reduced psychological distress and
improved wellbeing (Clift 2017). Songs can channel our senses
through musical elements, such as rhythms, melodies, and har-
monies, and enhance our emotional experience (Welch 2005).
Through increased neurochemical activity (such as dopamine and
oxytocin levels), singers experience pleasure, motivation, and a
sense of reward (Chanda 2013).
Social health
Participating in group singing, such as a choir, can reduce isola-
tion and provide social support. Taking part in group singing is re-
ported to increase neurochemicals (in particular oxytocin), which
is associated with bonding and social affiliation (Chanda 2013;
Keeler 2015; Kreutz 2014). Singing with others can promote pos-
itive feelings, such as friendship and empathy, which are positively
associated with a sense of wellbeing (Ryff 2008).
Why it is important to do this review
Non-pharmacological treatments for people living with PD play
an increasingly important role (IQWiG 2015). As discussed above,
evidence suggests that singing can be a beneficial complementary
therapy for people with PD (Vella-Burrows 2012). The number
of singing groups for people with PD in the community has been
fast-growing in high-income countries, such as the UK, Australia,
the USA, and Germany.
A recent review of music-based interventions in neurological reha-
bilitation highlighted the benefits of music for people with neuro-
logical conditions, including PD (Sihvonen 2017). However, the
review did not examine the specific effects of singing for people
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with PD. Another recent review on singing for people with PD
reported benefits of singing in people with PD, but this was a
narrative review and included non-randomised studies (Barnish
2016).
It is therefore timely to conduct a robust systematic review of the
efficacy of singing for people with PD, including an examination
of the effect of ‘dose’ of singing on relevant outcomes.
O B J E C T I V E S
To compare the efficacy and effectiveness of singing interventions
with non-singing intervention or usual care on QoL, wellbeing,
and speech and communication among people with PD. We will
assess the QoL and the physical, psychological, and social health
and wellbeing of people with PD who receive a singing interven-
tion, compared to non-singing intervention or usual care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) of singing
interventions versus non-singing interventions (e.g. listening to
music), or usual care. Placebo is not possible due to the nature of
the intervention. We will include trials that use both randomised
and quasi-randomised methods of allocation.
Types of participants
Individuals with medically diagnosed idiopathic PD, receiving
concurrent treatments.We will not place any restriction upon age,
sex, ethnicity, drug therapy, other treatments, disease severity, or
length of diagnosis. We will accept study authors’ statements that
participants were medically diagnosed.
Types of interventions
Singing interventions
Any singing interventions (e.g. group singing, choir, individual
singing training) facilitated by professionals with a relevant qualifi-
cation (e.g. music therapists, professional singing teachers, speech
therapists, musicians, nurses, occupational therapists, or physio-
therapists), with a minimum intervention length of two weeks.
We will also consider singing programmes delivered via virtual
technology, such as mobile phone applications or via websites, for
inclusion and will assess for their comparability to other types of
included singing interventions.
Comparison
Non-singing intervention (e.g. listening to music), or usual care
without singing.
Types of outcome measures
Primary outcomes
• QoL (e.g. Parkinson’s Disease Quesionnaire 39, World
Health Organization Quality of life Queistonnaire-brief version,
or other generic QoL measures, such as Short Form-36). PD-
specific QoL measures and generic instruments may not be
comparable, however, due to likely limited numbers of trials, we
will include both PD-specific and generic instruments.
• Wellbeing assessments (e.g. Warwick-Edinburgh Mental
Wellbeing Scale (WEMWBS), Quality of Well-Being Scale Self-
Administered (QWB-SA).
Secondary outcomes
• Speech and communication outcome measures (e.g.
acoustic characteristics, standardised quantitative intelligibility
assessments, standardised functional communication
assessments).
• Respiratory function (e.g. forced vital capacity (FVC),
forced expiratory volume-one second (FEV1), maximal
inspiratory pressure (MIP), and maximal expiratory pressure
(MEP)).
• Depression and anxiety (e.g. Hospital Anxiety and
Depression scale (HAD), Patient Health Questionnare-9 (PHQ-
9), Generalized Anxiety Disorder-7 (GAD-7), Depression
Anxiety Stress Scales (DASS)).
• Motor function (e.g. PD motor impairment rating scales,
such as Unified Parkinson’s Disease Rating Scales (UPDRS)
motor score, Part III, fall history, walking quantity and quality).
Adverse effects
We will include any time period of follow-up as stated in the stud-
ies. We will include singing versus usual care, or singing compared
with another non-singing intervention, such as listening to music.
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Search methods for identification of studies
Electronic searches
We will search the Cochrane Movement Disorders Group Spe-
cialised Trials Register. In addition, we will identify relevant arti-
cles through electronic searches, as described below.
In order to identify relevant studies wewill use the following search
terms.
• Parkinsonian Disorders or PD or Parkinsonism.
• Singing.
• Voice or vocal exercise or training.
• Choir.
• Music therapy.
We will search the following databases.
• Cochrane Database of Systematic Reviews (CDSR) EBM
Reviews Ovid (2005 to present) (Appendix 1).
• Cochrane Central Register of Controlled Trials
(CENTRAL) EBM Reviews Ovid (1991 to present).
• Database of Abstracts of Reviews of Effects (DARE). EBM
Reviews Ovid (1991 to 2015).
• MEDLINE Ovid (1946 to present) (Appendix 2).
• Embase Ovid (1974 to present) (Appendix 3).
• CINAHL EBSCOhost (1937 to present) (Appendix 4).
• British Nursing Index ProQuest (1985 to present)
(Appendix 5).
• PsycInfo Ovid (1806 to present) (Appendix 6).
• ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 7).
• World Health Organization International Clinical Trials
Registry Platform ( WHO ICTRP) ( www.who.int/trialsearch)
(Appendix 8).
• ZETOC ( The monitoring and search service for global
research publications) ( http://zetoc.jisc.ac.uk/) (Appendix 9).
We will not apply any date or language restriction. Translations of
non-English resources will be carried out if necessary.
Searching other resources
Wewill attempt to identify other published, ongoing, and planned
trials by performing the following.
• Inspecting references of all relevant studies.
• Searching trials registers such as ClinicalTrials.gov (
clinicaltrials.gov) and the WHO ICTRP ( apps.who.int/
trialsearch).
• Handsearching relevant conference proceedings (e.g. speech
pathologist conferences, PD/movement disorder conferences,
music therapy conferences, etc).
• Contacting authors of relevant retrieved studies.
Data collection and analysis
Selection of studies
Two review authors (JYI and EC) will screen, by title and abstract,
the articles identified by the search strategy.Wewill obtain the full-
text articles of potentially eligible studies, and two review authors
(JYI and EC) will screen these full-text articles. Any disagreements
will be resolved by consulting a third review author (MKY). We
will list any articles excluded after full-text assessment, and their
reasons for exclusion, in a ‘Characteristics of excluded studies’
table. We will illustrate the study selection process in a PRISMA
diagram.
Data extraction and management
Two review authors (JYI and MKY) will independently extract
data onto a data collection form, including citation details, trial
setting, inclusion and exclusion criteria, study population, inter-
vention details, outcome measures, and results. All review authors
involved in data extraction will be provided with detailed instruc-
tions. We will resolve any differences in opinion through discus-
sion or, if necessary, through independent arbitration by a third
review author (EC). We will attempt to contact study authors for
any additional information needed.Wewill collect as many details
as possible on participants including age at time of study, gender,
disease duration, presence of speech problem(s), and PD medica-
tion.
Assessment of risk of bias in included studies
Two review authors (JYI and EC) will independently assess the
methodological quality of the included trials using the criteria de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We will assess the following items for
each outcome in each included trial: sequence generation (ran-
domisation), allocation concealment, blinding of outcome asses-
sors, incomplete outcome data, and selective outcome reporting.
Due to the nature of the interventions, blinding of participants
and personnel is not applicable, however, as this causes a risk of
bias, we will assess this criterion. Where required, we will attempt
to contact corresponding authors to retrieve additional informa-
tion. All information will be collected on the data collection form
and any disagreements will be resolved through discussion.
Measures of treatment effect
We will calculate risk ratios (RR) with 95% confidence intervals
(CIs) for dichotomous outcomes. We will calculate mean differ-
ences (MD) or standardised mean differences (SMD) for contin-
uous outcomes, as appropriate. We will use Review Manager 5
software for all analyses (RevMan 2014).
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Unit of analysis issues
The primary data for analysis in the included studies will be indi-
vidual trial participants.
We will examine data from parallel-group RCTs and will aim to
use data from intention-to-treat analyses.
If data are presented at different periods of follow-up,wewill report
the same outcome separately each time it is presented, based on
the different periods of follow-up being reported. If the number
of studies cannot adequately populate these analyses, we will select
the longest period of follow-up for each study.
If the search identifies cross-over designs, we will utilise data from
the first period of the trial only, given the degenerative nature of PD
means a cross-over design is unlikely to be a suitablemethod for our
review question. If the search identifies cluster-randomised trials,
we will consult a statistician to assist in determining if themethods
of analysis used in the trial were appropriate. In this instance,
we will use the effect estimate and standard errors reported in
meta-analysis. If the methods of analysis used in the trial were
inappropriate, we will attempt to calculate the ‘effective sample
size’ of the trial for inclusion in meta-analysis as outlined in the
Cochrane Handbook for Systematic Reviews of Interventions, section
16.3.4 (Higgins 2011). If this is not possible, we will report the
results narratively.
Dealing with missing data
We will contact study authors to attempt to retrieve any missing
data. We will consider studies to be at low risk of bias if study
authors performed an intention-to-treat (ITT) analysis, or at high
risk of bias if study authors did not perform an ITT analysis. If this
is not possible due, for example, to the studies reporting aggregated
data, we will impute missing data based on best-case and worst-
case scenarios where possible. Where dropout is clearly identified
for an outcome, we will report the true number of participants
contributing to the data and will assess the potential impact of
the missing data. Furthermore, we will assess blinding of outcome
assessors and incomplete outcome data jointly.
Assessment of heterogeneity
We will consider heterogeneity firstly by considering the popu-
lations, settings, methods, and outcomes of the different studies.
If clinically important heterogeneity is present, we will not pool
the studies in a meta-analysis, but will describe them separately.
We will examine the Chi2 test and I2 statistic values for each out-
come. We will consider an I2 statistic estimate of 50% or more,
alongside a Chi2 test P value of 0.1 or less, to indicate important
heterogeneity. If there is heterogeneity, we will undertake pre-de-
fined subgroup and sensitivity analyses and will re-examine the
heterogeneity of these results separately.
Assessment of reporting biases
In the event of multiple publications of the same study, we will
list the subsequent papers with the main paper and only enter
data once. If there is uncertainty in this respect, we will attempt
to contact the study authors. We will assess publication bias by
examining funnel plots, if we have a sufficient number of included
studies (at least 10). In the event of funnel plot asymmetry, we will
assess possible reasons for this and report these descriptively.
Data synthesis
We will perform a random-effects model meta-analysis, as we an-
ticipate that there is unlikely to be one true effect across the in-
cluded studies due to variations of the intervention and other dif-
ferences between studies. If we are unable to perform a meta-anal-
ysis due to substantial differences between the studies, or when
only one study is identified for inclusion, we will report findings
narratively, paying attention to the size, consistency, and direction
of effect. Where we have included studies, we will create a ‘Sum-
mary of findings’ table for the comparison ‘Singing compared to
usual care without singing’, and a ‘Summary of findings’ table for
the comparison ‘Singing compared to non-singing intervention’.
We will include the primary outcomes and adverse effects in the
‘Summary of findings’ tables. We will use the GRADE considera-
tions (study limitations, consistency of effect, precision, directness
of evidence, publication bias, magnitude of effect, dose-response
gradient, and plausible confounding that could reduce effect size)
to assess the quality of the body of evidence generated by the in-
cluded studies that contribute data to these outcomes. We will
perform GRADE assessments using GRADEpro GDT software
(GRADEpro 2015). We will specify all decisions to downgrade or
upgrade the quality of the body of evidence in footnotes.
Wewill perform subgroup analyses as possible (as described below)
if we identify heterogeneity.
Subgroup analysis and investigation of heterogeneity
• Duration of PD diagnosis (i.e. time since formal diagnosis <
10 years; 10 to 15 years; > 15 years).
• Severity of PD (according to Hoehn and Yahr staging of
PD (Bhidayasiri 2012) , UPDRS).
• Age group (e.g. ≤ 65 years versus > 65 years) utilising mean
ages in each trial (if we are unable to get full age spread from the
study authors).
• Singing intervention length (e.g. brief (less than six weeks),
short-term (6 weeks to 3 months), versus long-term (≥ six
months)).
• Type of singing practitioner and their training (formally
trained music or singing professional versus health or lay
professional).
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If a sufficient number of trials meet the inclusion criteria of this
review to make this meaningful, we will perform these subgroup
analyses whether we find heterogeneity is present or not.
Sensitivity analysis
Wewill perform sensitivity analyses, regardless of whether we iden-
tify heterogeneity or not, to assess the impact ofmissing data on the
pooled estimate(s) of meta-analyses. If we find that heterogeneity
is present, we will perform sensitivity analyses to assess the impact
of the heterogeneity on the pooled estimate(s) of meta-analyses.
Furthermore, if cross-over or cluster randomised studies meet the
inclusion criteria of the review, we will conduct sensitivity analyses
to assess the impact of inclusion of these designs on the pooled
estimate(s) of meta-analyses, irrespective of whether heterogeneity
is present or not.
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A D D I T I O N A L T A B L E S
Table 1. Glossary
Terms Definitions
Dysarthria A collective name for a group of speech disorders resulting from disturbances in muscular control of the speech
mechanism due to damage of the nervous system. It includes harsh and breathy voice quality, reduced overall
loudness, mono-loudness, mono-pitch, reduced prosody, lower overall speaking pitch, slurred speech, illogical
pauses, and short rushes of speech
Bradykinesia Slowness of movement
Hyposmia A reduced ability to smell and to detect odours
Dyskinesia A movement disorder, characterised by involuntary muscle movements
Dystonia A movement disorder in which a person’s muscles contract uncontrollably
Motor fluctuations Periods of the day with poor or no response to medication (off time). This alternates with periods of improved
function (on time)
Oedema A condition characterised by an excess of watery fluid collecting in the cavities or tissues of the body
Somnolence Alternatively “sleepiness” or “drowsiness”; a state of strong desire for sleep, or sleeping for unusually long periods
Hallucinations Someone sees, hears, smells, tastes, or feels things that don’t exist outside their mind
Phonation The production or utterance of speech sounds.
8Singing for people with Parkinson’s disease (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Glossary (Continued)
Auditory cueing The process whereby movement is synchronized to sound (Schaefer 2014).
Rhythm The time-based pattern of music or sound, including beats and accents (Kennedy 2007).
A P P E N D I C E S
Appendix 1. CDSR/CENTRAL/DARE (EBM Reviews, Ovid) search strategy
#1 exp Parkinson’s Disease/
#2 parkinson*.mp
#3 #1 OR #2
#4 exp singing/
#5 (singing OR singer).mp
#6 ((voice* or vocal*) adj3 (exercis* or train*)).mp
#7 (choir OR choral).mp
#8 exp music therapy/
#9 music therapy.mp
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
Appendix 2. MEDLINE (Ovid) search strategy
#1 exp Parkinsonian Disorders/
#2 parkinson*.mp
#3 #1 OR #2
#4 singing/
#5 (singing OR singer).mp
#6 ((voice* or vocal*) adj3 (exercis* or train*)).mp
#7 (choir OR choral).mp
#8 music therapy/
#9 music*.mp
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
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Appendix 3. Embase (Ovid) search strategy
#1 exp Parkinsonian Disorders/
#2 parkinson*.mp
#3 #1 OR #2
#4 singing/
#5 (singing OR singer).mp
#6 ((voice* or vocal*) adj3 (exercis* or train*)).mp
#7 (choir OR choral).mp
#8 music therapy/
#9 music*.mp
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
Appendix 4. CINAHL (EBSCOhost) search strategy
#1 MH “Parkinsonian Disorders+”
#2 parkinson*
#3 #1 OR #2
#4 MH “singing”
#5 singing OR singer
#6 (voice* or vocal*) N3 (exercis* or train*)
#7 choir OR choral
#8 MH music therapy
#9 music therapy
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
Appendix 5. British Nursing Index (ProQuest) search strategy
parkinson* AND ((sing* OR singer) OR ((voice* OR vocal*) NEAR/3 (exercis* OR train*)) OR (choir OR choral) ORmusic therapy)
Appendix 6. PsycInfo (Ovid) search strategy
#1 exp Parkinson’s Disease/
#2 parkinson*.mp
#3 #1 OR #2
#4 exp singing/
#5 (singing OR singer).mp
#6 ((voice* or vocal*) adj3 (exercis* or train*)).mp
#7 (choir OR choral).mp
#8 exp music therapy/
#9 music therapy.mp
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
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Appendix 7. ClinicalTrials.gov search strategy
Condition/Disease: Parkinson OR parkinsonism OR parkinsonian
Other: sing OR signing OR singer OR voice exercise OR voice trainer OR vocal exercise OR vocal trainer OR choir OR choral OR
music therapy
Appendix 8. World Health Organization International Clinical Trials Registry Platform (WHO
ICTRP) search strategy
Condition/Disease: Parkinson OR parkinsonism OR parkinsonian
Intervention: sing OR signing OR singer OR voice exercise OR voice trainer OR vocal exercise OR vocal trainer OR choir OR choral
OR music therapy
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